^
    Back
    Association details:
    Biomarker:KRT7 expression + MUC1 expression
    Cancer:Ampulla of Vater Carcinoma
    Drug:gemcitabine (DNA synthesis inhibitor) +
    albumin-bound paclitaxel (Bcl2 inhibitor, Tubulin inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    Cancer Med
    Title:

    Durable response for ampullary and duodenal adenocarcinoma with a nab-paclitaxel plus gemcitabine ± cisplatin combination

    Published date:
    07/01/2019
    Excerpt:
    Positive IHC staining for CK7 and MUC1 was consistent with pancreatobiliary‐type ampullary adenocarcinoma. Chemotherapy was decided to switch to gemcitabine 400 mg/m2 and nab‐paclitaxel 125 mg/m2 weekly. The patient's cancer‐related bony pain rapidly reduced...The gemcitabine and nab‐paclitaxel regimen has been continued, with an ongoing tumor response for >1 year...
    DOI:
    10.1002/cam4.2181